TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12823075

Group type: EXPERIMENTAL
Intervention: Low-dose risperidone (starting dose of 0.25 mg/day, titrated upward to 2 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10859225

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg (tid, sc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg (tid, sc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 and 60 microg)
Number of subjects: 0
Study: 8860007

Group type: EXPERIMENTAL
Intervention: G6PD deficiency subjects (n=18)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Electrophoresis on 166 samples
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: G6PD deficient subjects (n=18)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Genotyping of G6PD deficient subjects (n=18)
Number of subjects: 166
Study: 1514347

Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular ketamine (1 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pethidine (1 mg/kg)
Number of subjects: 30
Study: 6088248

Group type: EXPERIMENTAL
Intervention: CCNU, cyclophosphamide, vincristine and methotrexate (CCOM) with consolidation locoregional radiation (30 Gy) after two courses of chemotherapy for LD patients.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Maintenance chemotherapy after consolidation radiotherapy for a subset of 12 LD patients achieving CR.
Number of subjects: 57
Study: 31058762

Group type: EXPERIMENTAL
Intervention: Morning exercise (AM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Afternoon exercise (PM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (rested)
Number of subjects: 16
Study: 29890368

Group type: EXPERIMENTAL
Intervention: Light Virtual Reality training program
Number of subjects: 60

Group type: COMPARATOR
Intervention: User manual
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed-base simulator
Number of subjects: 60
Study: 27251974

Group type: EXPERIMENTAL
Intervention: EMD + ABG (combination group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMD alone (EMD group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: OFD (control group)
Number of subjects: 12
Study: 24344912

Group type: EXPERIMENTAL
Intervention: Filtek LS Low Shrink Posterior Restorative
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tetric EvoCeram
Number of subjects: 31
Study: 23387216

Group type: EXPERIMENTAL
Intervention: HX0507 (3 mg/kg and 8 mg/kg or above)
Number of subjects: 80
Study: 21053621

Group type: EXPERIMENTAL
Intervention: Yinian Jiangya Yin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Tianma Gouteng Yin
Number of subjects: 79
Study: 17175564

Group type: EXPERIMENTAL
Intervention: Warfarin (dose-adjusted, INR 2.0-3.0)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aspirin (300 mg)
Number of subjects: 75
Study: 15838335

Group type: EXPERIMENTAL
Intervention: Cerivastatin (800 mug)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 11853280

Group type: EXPERIMENTAL
Intervention: Menatetrenone-4 plus elemental calcium carbonate 800 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Elemental calcium carbonate 800 mg/day
Number of subjects: 83
Study: 9596112

Group type: EXPERIMENTAL
Intervention: ABT-761 (200 mg orally, 5 h prior to exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (matched placebo, 5 h prior to exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ABT-761
Number of subjects: 10
Study: 7816491

Group type: EXPERIMENTAL
Intervention: Steroid group (group S, n = 14) received 0.5% lidocaine plus triamcinolone acetonide (10 mg/ml).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Steroid plus morphine group (group S + M, n = 10) received the same combination plus 2.5 mg of morphine sulphate.
Number of subjects: 24
Study: 3354495

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of retinyl palmitate (100,000 IU, or 30 mg retinol equivalent)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin A injections
Number of subjects: 30
Study: 31464511

Group type: EXPERIMENTAL
Intervention: Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 30005809

Group type: EXPERIMENTAL
Intervention: Structured peer-feedback (PF)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Faculty-feedback (FF)
Number of subjects: 59
Study: 28483685

Group type: EXPERIMENTAL
Intervention: Low-load exercise of shoulder muscles
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inactive ultrasound for 10 minutes (placebo)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (including low-load exercise)
Number of subjects: 90
Study: 25992985

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 16
Study: 23742659

Group type: EXPERIMENTAL
Intervention: High Protein (HP) yogurt (14.0 g protein)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal Protein (NP) yogurt (5.0 g protein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HP yogurt
Number of subjects: 32

Group type: COMPARATOR
Intervention: NP yogurt
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HP yogurt and NP yogurt
Number of subjects: 32
Study: 21339275

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 200
Study: 19376240

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin (females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin (males)
Number of subjects: 0
Study: 15848571

Group type: EXPERIMENTAL
Intervention: Sirolimus (SL) 3 mg/d for African Americans; 2 mg/d for others, starting on days 2 and 3, adjusted to 8 to 10 ng/d by weeks 3 to 4 posttransplant.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) levels 15 to 20 ng/mL, progressively reduced to 5 ng/mL by 3 months.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Basiliximab (BX) induction, TAC, and steroids without SL (Group 2).
Number of subjects: 152
Study: 11915062

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levo-bupivacaine 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.25%
Number of subjects: 60
Study: 9620309

Group type: EXPERIMENTAL
Intervention: UVB radiation
Number of subjects: 0
Study: 7621742

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation with 10 Gy in 5 fractions
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation with 7 Gy in one fraction
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation during the first 4 postoperative days
Number of subjects: 216

Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 216
Study: 2201413

Group type: EXPERIMENTAL
Intervention: Myrcia uniflora
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bauhinia forficata
Number of subjects: 54
Study: 343995

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone plus 10% urea ('Alphaderm')
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.1% betamethasone 17-valerate
Number of subjects: 21
Study: 30528227

Group type: EXPERIMENTAL
Intervention: rhHNS IT 45 mg administered every 2 weeks (Q2W)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhHNS IT 45 mg administered every 4 weeks (Q4W)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 21
Study: 29051306

Group type: EXPERIMENTAL
Intervention: Thermoneutral head out water immersion (HOWI)
Number of subjects: 0
Study: 25830421

Group type: EXPERIMENTAL
Intervention: Beta-lactam monotherapy
Number of subjects: 2283

Group type: COMPARATOR
Intervention: Beta-lactam-macrolide combination therapy
Number of subjects: 2283

Group type: COMPARATOR
Intervention: Fluoroquinolone monotherapy
Number of subjects: 2283
Study: 23850227

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study: 21463520

Group type: EXPERIMENTAL
Intervention: intensive treatment plus the facilitator‐led individual behaviour change intervention (n = 239)
Number of subjects: 478

Group type: COMPARATOR
Intervention: intensive treatment alone (n = 239)
Number of subjects: 478
Study: 19826393

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 2.5 mg injections at 4-week intervals
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham procedure (subconjunctival normal saline)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (IVB and control)
Number of subjects: 26
Study: 16478882

Group type: EXPERIMENTAL
Intervention: ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone)
Number of subjects: 533

Group type: COMPARATOR
Intervention: MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine)
Number of subjects: 533

Group type: COMPARATOR
Intervention: MOPP/ABV with RT (subtotal nodal irradiation)
Number of subjects: 533

Group type: COMPARATOR
Intervention: ABVPP with RT (subtotal nodal irradiation)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Consolidation CT (chemotherapy)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: RT (subtotal nodal irradiation)
Number of subjects: 533
Study: 14739801

Group type: EXPERIMENTAL
Intervention: Fluid administration (7 ml/kg hydroxyethyl starch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vasopressor (0.2 mg/kg ephedrine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 12
Study: 11282812

Group type: EXPERIMENTAL
Intervention: External self-exposure treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interoceptive self-exposure treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined external and interoceptive self-exposure treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 9093301

Group type: EXPERIMENTAL
Intervention: Three doses of five-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 51
Study: 7653738

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (eye-drops and nasal spray)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 95
Study: 3150824

Group type: EXPERIMENTAL
Intervention: Combination of luteinizing hormone‐releasing analogue (GnRHa, Buserelin) and pulsatile administration of hMG (Group I)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pulsatile hMG administration alone (Group II)
Number of subjects: 9
Study: 28816509

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 12.5-25 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS)
Number of subjects: 264
Study: 27443485

Group type: EXPERIMENTAL
Intervention: Standard quitline plus weight management program (simultaneously)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Standard quitline plus weight management program (sequentially)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Standard quitline
Number of subjects: 2550
Study: 23774079

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 52
Study: 23477890

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg IV four times per week)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No Amifostine
Number of subjects: 243
Study: 20801495

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6505
Study: 18158380

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) therapy (six nights of total SD, separated by recovery sleep)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No Sleep Deprivation therapy (Control group)
Number of subjects: 19
Study: 16419700

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nimeisulide (oral administration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 654-2 (injection)
Number of subjects: 90
Study: 12074345

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated Palmaz-Schatz stents
Number of subjects: 40
Study: 10405080

Group type: EXPERIMENTAL
Intervention: Dimensional representations of psychotic psychopathology
Number of subjects: 706

Group type: COMPARATOR
Intervention: Categorical representations of psychotic psychopathology
Number of subjects: 706
Study: 7748214

Group type: EXPERIMENTAL
Intervention: Every-other-week methotrexate (MTX)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Weekly methotrexate (MTX)
Number of subjects: 47
Study: 2178379

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study: 36066

Group type: EXPERIMENTAL
Intervention: Compound A (Actified)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Compound B (Dristan)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall performance (MTPB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Problem solving tasks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Physiological parameters and subjective evaluations
Number of subjects: 14
Study: 31449573

Group type: COMPARATOR
Intervention: Acellular dermal matrix graft (ADMG) used as a membrane with guided bone regeneration.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: No membrane on buccal overlay graft, ADMG used only to cover the occlusal surface.
Number of subjects: 24
Study: 28241247

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg every 6 hours)
Number of subjects: 73
Study: 26061092

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX)
Number of subjects: 103
Study: 24218952

Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g tid) combined with bromocriptine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bromocriptine alone
Number of subjects: 40
Study: 20674417

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ondansetron
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5 mg/kg metoclopramide
Number of subjects: 100
Study: 19188677

Group type: EXPERIMENTAL
Intervention: Low-fat breakfast
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 27
Study: 16925009

Group type: EXPERIMENTAL
Intervention: Single-visit approach (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two-visit approach without intracanal dressing (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two-visit approach using calcium hydroxide as an intracanal dressing for one week (Group C)
Number of subjects: 60
Study: 15610569

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine hydrochloride gel (20 mL of 2% lidocaine gel administered 15 minutes before biopsy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (20 mL of ultrasound gel administered under the same conditions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine hydrochloride gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11460891

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine monotherapy (2400 mg/day)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy (600, 1200, 2400 mg/day)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine monotherapy
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine treatment
Number of subjects: 692
Study: 10936472

Group type: EXPERIMENTAL
Intervention: High-dose willow bark extract (240 mg salicin)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Low-dose willow bark extract (120 mg salicin)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 8725599

Group type: EXPERIMENTAL
Intervention: H2 blocker (famotidine 20mg orally at 9 pm the day before and 2hs before anesthesia)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Preoperative drinking (clear fluids until 2hs before anesthesia)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no eating or drinking from 9 pm the day before surgery, 500 ml maintenance fluid before anesthesia)
Number of subjects: 63
Study: 1483495

Group type: EXPERIMENTAL
Intervention: Propranolol pretreatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide with Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide without Propranolol
Number of subjects: 12
Study: 3936192

Group type: EXPERIMENTAL
Intervention: Automated procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-automated procedures
Number of subjects: 0
Study: 30527263

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3.0 g/d of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 23
Study: 26329534

Group type: EXPERIMENTAL
Intervention: Postal mail delivery method
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Email delivery method
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Hybrid approach (postal and electronic)
Number of subjects: 7200
Study: 24646809

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 36
Study: 22728482

Group type: EXPERIMENTAL
Intervention: Adefovir plus Entecavir (ADV + ETV) combination therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Adefovir monotherapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Adefovir plus Lamivudine (ADV + LAM) therapy
Number of subjects: 91
Study: 19941906

Group type: EXPERIMENTAL
Intervention: efavirenz+Kivexa
Number of subjects: 126

Group type: COMPARATOR
Intervention: lopinavir/r+Kivexa
Number of subjects: 126
Study: 17921037

Group type: EXPERIMENTAL
Intervention: 5‐HT1AR BP in depressed subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 16042643

Group type: EXPERIMENTAL
Intervention: LAAM (three doses per week)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Methadone (daily dosing)
Number of subjects: 315
Study: 12152003

Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10406066

Group type: EXPERIMENTAL
Intervention: Primary stenting for acute myocardial infarction
Number of subjects: 0
Study: 7762051

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 245

Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 245
Study: 2280233

Group type: EXPERIMENTAL
Intervention: Cod liver oil (20 ml daily for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cod liver oil for 6 weeks)
Number of subjects: 0
Study: 30787899

Group type: EXPERIMENTAL
Intervention: Daily 10-min classroom-based exercise break of moderate to vigorous intensity for 9 weeks
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 512
Study: 28866466

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use after the 2007 NICE guidelines
Number of subjects: 51649

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use after the 2011 AAP guidelines
Number of subjects: 51649

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use in children 3 to 10 years old
Number of subjects: 51649

Group type: EXPERIMENTAL
Intervention: Incidence of vesicoureteral reflux
Number of subjects: 51649
Study: 27055960

Group type: EXPERIMENTAL
Intervention: Canola oil (CO)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sunflower oil (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comparison between RBO and CO
Number of subjects: 75
Study: 24526579

Group type: COMPARATOR
Intervention: Continuous Endurance Training (ET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Repeated Sprint Training (RST)
Number of subjects: 23
Study: 23067364

Group type: EXPERIMENTAL
Intervention: Multifactorial interdisciplinary intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 241
Study: 20845101

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 82
Study: 17765354

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (DG) - gemcitabine 1100mg/m² on days 1 and 8, docetaxel 75mg/m² on day 8
Number of subjects: 312

Group type: COMPARATOR
Intervention: Single-agent docetaxel (D) - docetaxel 100mg/m² on day 1
Number of subjects: 312
Study: 15949119

Group type: EXPERIMENTAL
Intervention: Immunochemical test (OC-Hemodia)
Number of subjects: 7332

Group type: COMPARATOR
Intervention: Guaiac test (Hemo-Fec)
Number of subjects: 7332
Study: 12573788

Group type: EXPERIMENTAL
Intervention: High-resolution B-mode sonography with color flow Doppler
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Power-mode Doppler sonography
Number of subjects: 90

Group type: COMPARATOR
Intervention: B-mode sonography
Number of subjects: 90
Study: 10786204

Group type: EXPERIMENTAL
Intervention: Fenoterol (4 x 100 mcg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ipratropium bromide (4 x 40 mcg daily)
Number of subjects: 44